Copyright
©The Author(s) 2021.
World J Hepatol. Oct 27, 2021; 13(10): 1269-1288
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1269
Published online Oct 27, 2021. doi: 10.4254/wjh.v13.i10.1269
Table 1 Clinical characteristics and outcome of non-cirrhotic portal fibrosis in pediatric studies
Parameters | Prasad et al[90] (n = 45) | Sood et al[91] (n = 19) | Poddar et al[109] (n = 11) | Franchi-Abella et al[110] (n = 48) | |
Mean or median (range) age at presentation | 14.5 (6-18) yr | 13.8 (5.9-17.6) yr | 11 (5-14) yr | 8.75 (1 mo-16 yr) | |
At presentation | |||||
Variceal bleed | 49% | 15.70% | 54.60% | 18.80% | |
Lump upper abdomen | 47% | 84.20% | 45.40% | 43.80% | |
Ascites | 20% | - | 18% | - | |
Spleen size (mean) cm | 10.5 | 12 (4.75–17.25) | 8 | - | |
Variceal recurrence | 39% | - | 18% | - | |
Poor outcome | |||||
Decompensation | 4% | 0 | 0 | 12.50% | |
Hepatopulmonary syndrome | 2% | 5% | - | 4.20% | |
Follow-up duration (mean) | 48 (3-120) mo | 18 (2-51) mo | 57.5 (12-78) mo | 15 (1-26) yr | |
Survival without transplant | 93% | 100% | 100% | 88% |
- Citation: Sarma MS, Seetharaman J. Pediatric non-cirrhotic portal hypertension: Endoscopic outcome and perspectives from developing nations. World J Hepatol 2021; 13(10): 1269-1288
- URL: https://www.wjgnet.com/1948-5182/full/v13/i10/1269.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i10.1269